Kobayashi Pharmaceutical First Quarter 2025 Earnings: Misses Expectations

Simply Wall St · 05/10 23:42

Kobayashi Pharmaceutical (TSE:4967) First Quarter 2025 Results

Key Financial Results

  • Revenue: JP¥32.6b (down 11% from 1Q 2024).
  • Net income: JP¥1.62b (up 66% from 1Q 2024).
  • Profit margin: 5.0% (up from 2.7% in 1Q 2024).
  • EPS: JP¥21.85 (up from JP¥13.13 in 1Q 2024).
earnings-and-revenue-growth
TSE:4967 Earnings and Revenue Growth May 10th 2025

All figures shown in the chart above are for the trailing 12 month (TTM) period

Kobayashi Pharmaceutical Revenues and Earnings Miss Expectations

Revenue missed analyst estimates by 6.6%. Earnings per share (EPS) also missed analyst estimates by 56%.

Looking ahead, revenue is forecast to grow 4.5% p.a. on average during the next 3 years, compared to a 3.8% growth forecast for the Personal Products industry in Japan.

Performance of the Japanese Personal Products industry.

The company's share price is broadly unchanged from a week ago.

Risk Analysis

Before we wrap up, we've discovered 3 warning signs for Kobayashi Pharmaceutical that you should be aware of.